These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38862303)

  • 1. Response to "Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis". Response to related letter.
    De La Flor JC; Moral E; Deira J; Monzón T; Valga F; Albarracín C; Rodeles M
    Nefrologia (Engl Ed); 2024; 44(3):444-446. PubMed ID: 38862303
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis.
    González Sanchidrián S; Gallego Domínguez S; Jiménez Mayor E; Labrador Gómez PJ; Deira Lorenzo J
    Nefrologia (Engl Ed); 2024; 44(3):442-444. PubMed ID: 38871561
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 4. Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
    Pace E; Tingen J
    Am Fam Physician; 2017 Oct; 96(8):540-542. PubMed ID: 29094890
    [No Abstract]   [Full Text] [Related]  

  • 5. Two new doses of dulaglutide (Trulicity) for diabetes.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):168. PubMed ID: 33429412
    [No Abstract]   [Full Text] [Related]  

  • 6. Dulaglutide: first global approval.
    Sanford M
    Drugs; 2014 Nov; 74(17):2097-103. PubMed ID: 25367716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.
    Tong G; Lu S; Kuang H; Li Y; Deng Y; Lou Y; Wang W; Zhu D
    Diabetes Obes Metab; 2024 Apr; 26(4):1540-1543. PubMed ID: 38185739
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
    Ayesh H; Ayesh S; Niswender K
    Am J Ther; 2024 Jul-Aug 01; 31(4):e523-e527. PubMed ID: 38976545
    [No Abstract]   [Full Text] [Related]  

  • 9. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus.
    Burlina S; Dalfrà MG; Caprino R; Lapolla A
    Acta Diabetol; 2023 Jan; 60(1):137-138. PubMed ID: 36136154
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
    Guo L; Xi Y; Li L; Guo K; Wu J; Xu J; Wang Y; Wu G; Si S
    Diabetes Obes Metab; 2024 Jul; 26(7):2979-2983. PubMed ID: 38600796
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
    Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
    Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
    Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
    J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
    Da Porto A; Casarsa V; Colussi G; Catena C; Cavarape A; Sechi L
    Diabetes Metab Syndr; 2020; 14(4):289-292. PubMed ID: 32289741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
    Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
    Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.